glpletter — Page 7

GIP agonists drive weight loss through pancreatic, adipose, and brain mechanisms.

DPP-4 degrades GLP-1 in minutes, forcing drug engineers to rebuild the molecule for survival.

GLP-1 receptors throughout the body trigger effects far beyond blood sugar control.

How dual agonists protect against low blood sugar while controlling high blood sugar.

Enzymatic degradation and receptor binding geometry define every structural choice.

cAMP amplification explains why GLP-1 drugs safely lower blood sugar.

Nanoparticles could protect peptide drugs from rapid degradation in the body.

Human imaging confirmed insulin reaches the brain via nasal delivery within thirty minutes.

Enzymes, mucus, tight junctions, and efflux pumps each block oral peptides.

Nausea from GLP-1s triggers through both brain and gut pathways simultaneously.

Brain GLP-1R signaling reaches beyond appetite into addiction and dementia.